FIG. 1A

Degradant (PF-07086920)
Percentage in Formulations Comprising 9% HG and 0% BHT




FIG. 1B

Degradant (PF-07086920)
Percentage in Formulations Comprising 9% HG and 0.1% BHT




FIG. 2A

Degradant (PF-07086920)
Percentage in Formulations Comprising 5% HG and 0% BHT




FIG. 2B

Degradant (PF-07086920)
Percentage in Formulations Comprising 5% HG and 0.1% BHT




FIG. 3A



Degradant (PF-07086920)
Percentage in Formulations Comprising 2% HG and 0% BHT
2% HG, 0% BHT
PF-07086920 Degradant (%)
4.00
3.50
3.00
2.50
2.00
1.50
1.00
0.50
0.00
0.01%
0.03%
0.1%
5C
25C
40C
1 month
3 months
6 months
12 months

FIG. 3B



Degradant (PF-07086920)
Percentage in Formulations Comprising 2% HG and 0.1% BHT
2% HG, 0.1% BHT
PF-07086920 Degradant (%)
4.00
3.50
3.00
2.50
2.00
1.50
1.00
0.50
0.00
0.01%
0.03%
5C
25C
40C
1 month
3 months
6 months

FIG. 4



Degradant (PF-07086920)
Percentage in Formulations Comprising:
9% HG and 0% BHT; 5% HG and 0% BHT; 2% HG and 0% BHT
9% HG, no BHT
5% HG, no BHT
2% HG, no BHT
PF-07086920 Degradant (%)
3.00
2.50
2.00
1.50
1.00
0.50
0.00
0.01%
0.03%
0.01%
0.03%
0.01%
0.03%
5C 25C 40C 5C 25C 40C 5C 25C 40C 5C 25C 40C 5C 25C 40C 5C 25C 40C
Initial
1 month
3 months
6 months

FIG. 5

Preparation (270 Kg) of Topical Formulations of the Present Invention Comprising PF-07038124




FIG. 6

Pooling, Phase Separation of the Phase I Formulation comprising of 9% HG and 0.1% BHT Subsequent to Static Resting Overnight at 29°C to 35°C in the Jacketed Holding Tank




FIG. 7

No Pooling, No Phase Separation of a topical formulation comprising 5% HG and essentially free of BHT Subsequent to Static Resting Overnight at 29°C to 35°C in the Jacketed Holding Tank

